Bevacizumab-based therapy for advanced small bowel adenocarcinoma

Gut

Volumn 57, Issue 11, 2008, Pages 1631-1632

  Tsang, H ^a   Yau, T ^a   Khong, P L ^a   Epstein, R J ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; GEMCITABINE; OXALIPLATIN; VASCULOTROPIN;

ABDOMINAL PAIN; ADENOCARCINOMA; ADVANCED CANCER; AGED; ANEMIA; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LETTER; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SMALL INTESTINE CARCINOMA; SYMPTOM; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 54349111198     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2008.153866     Document Type: Letter

References (10)

1. ten Kate GL, Kleibeuker JH, Nagengast FM, et al. Is surveillance of the small bowel indicated for Lynch syndrome families? Gut 2007;56:1198-201.
2. Hawker PC, Gyde SN, Thompson H, et al. Adenocarcinoma of the small intestine complicating Crohn's disease. Gut 1982;23:188-93.
3. Rampertab SD, Forde KA, Green PH. Small bowel neoplasia in coeliac disease. Gut 2003;52:1211-4.
4. Bulut K, Pennartz C, Felderbauer P, et al. Vascular endothelial growth factor (VEGF164) ameliorates intestinal epithelial injury in vitro in IEC-18 and Caco-2 monolayers via induction of TGF-beta release from epithelial cells. Scand J Gastroenterol 2006;41:687-92.
5. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-35.
6. Kummar S, Ciesielski TE, Fogarasi MC. Management of small bowel adenocarcinoma. Oncology (Williston Park, NY) 2002;16:1364-9; discussion 70, 72-3.
7. Epstein RJ. VEGF signaling inhibitors: more proapoptotic than anti-angiogenic. Cancer Metastasis Rev 2007;26:443-52.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
9. Hodde JP, Suckow MA, Wolter WR, et al. Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats. J Surg Res 2004;120:189-94.
10. Thomson Lonborg J, Vilmar A, Mard D, et al. Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer. Oncol Rep 2007;18:1023-9.